Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

Bullboard Posts
Post by Lynx9on Jan 08, 2015 5:32pm
121 Views
Post# 23300023

Nasdaq Listing

Nasdaq Listinghttps://listingcenter.nasdaqomx.com/assets/initialguide.pdf

There are many requirements to become listed on nasdeq, all of which AMF does not meet yet.

What to look forward to for amf is a very serious reverse split of shares (min 20 to 1 but more probable is 50 to 1) so they can maintain at least a us $4 price and maintain it at that level, $5million in the bank, market makers, at least 300 share holders, meet US accounting rules, all of which is attainable if and only if amf can attract one or many possible partners with deep pockets and at which time we as long term shareholders will be raped and pillaged as new money slowly takes over. By the way, this takes time so if you think this is going to happen over night your dreaming so have a few more shots of tequilla, your going to need it!

I'm on my last bottle of scotch myself and can't afford another.

Bullboard Posts